Skip to main content

Table 6 Drug-related treatment-emergent adverse events ≥1% in either treatment group (SAF)

From: Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)

TEAEs, n (%)Placebo (n = 442)Mirabegron Total (n = 445)
Drug-related TEAEsa57 (12.9)84 (18.9)
 Dry mouth7 (1.6)6 (1.3)
 Nausea3 (0.7)6 (1.3)
 Constipation4 (0.9)3 (0.7)
 Diarrhea1 (0.2)5 (1.1)
 Headache7 (1.6)18 (4.0)
 Dizziness6 (1.4)2 (0.4)
 Somnolence1 (0.2)2 (0.4)
 Escherichia urinary tract infection7 (1.6)9 (2.0)
 Fatigue10 (2.3)7 (1.6)
  1. aPossible or probable, as assessed by the investigator, or where relationship was missing
  2. SAF safety analysis set, TEAEs treatment-emergent adverse events
\